Kancera appoints Robert Edfors as Chief Medical Officer

Kancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine, has up until now been the company’s Chief Scientific Officer and Senior Vice President Clinical Development.

Robert will continue to be scientifically responsible for the company’s research and development and will also assume the overall medical responsibility. Markus Jerling, Kancera’s former CMO on a part-time consulting basis, is leaving the company.

“The appointment of Robert Edfors as new CMO underlines our strong focus on cardiovascular diseases. I would like to express my gratitude to Markus Jerling who, with his deep knowledge in clinical pharmacology and extensive drug development experience, has played an instrumental role in the KAND145 phase I study and phase Ib-part of the KANDOVA-study,” says Peter Selin CEO at Kancera.

About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company’s Certified Adviser.

For further information:
Visit Kancera’s website: www.kancera.com

or contact:
ir@kancera.com or phone: +46 (0)8-5012 60 80